-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23, the official website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration of China announced that Eli Lilly and Company had applied for clinical trials
A monoclonal antibody that binds to and excites the PD-1 receptor, with the potential to become a "first-in-class" therapy, has completed a Phase 2 clinical trial overseas for the treatment of rheumatoid arthritis
Screenshot source: CDE official website
The PD-1 target has played an extremely important role
The PD-1 target has played an extremely important role
Screenshot Source: References[3]
Peresolimab Injection (LY3462817), developed by Eli Lilly, is a PD-1 agonist that is being studied for the treatment of rheumatoid arthritis and other autoimmune diseases
Research is underway to treat rheumatoid arthritis and other autoimmune diseases that bind to human PD-1 and act as its agonist, inhibiting the activation and expansion of lymphocytes
A Phase 2 study evaluating the efficacy and safety of LY3462817 in patients with moderate to severely active rheumatoid arthritis has been completed
In the global context, drug development for PD-1 for autoimmune diseases is not active
It is expected that Eli Lilly's PD-1 receptor agonist will progress smoothly in clinical research and make an early breakthrough to bring new treatment options
Resources:
Resources:[1] China State Food and Drug Administration Drug Evaluation Center (CDE) official website.
[1] China State Food and Drug Administration Drug Evaluation Center (CDE) official website.
Zheng Zhongqing,Jiao Guohui,Guo Liping.
[3] Eli Lilly R&D Activity Day 2021 PPT